Participated · Seed · Mar 2026

ImmuneBridge develops a cell therapy screening and manufacturing platform that combines machine-learning-enabled donor selection with a proprietary small molecule that preserves stem-cell pluripotency through repeated replications. This approach enables differentiation into T cells, NK cells, macrophages, or neutrophils and can produce thousands of high-quality doses from a single donor versus the industry standard of tens of doses. The company is shifting to a "picks and shovels" model by licensing its platform to external co-development partners, from startups to large pharma, and is already working with over a dozen collaborators. Following its recent financing, ImmuneBridge promoted Dr. Nina Horowitz to CEO and appointed Dr. Rui Tostoes as CTO to lead the scale-up of manufacturing. Financially, the company raised $7.7M in a second seed round led by NFX, bringing total seed funding to nearly $20M. ImmuneBridge aims to advance initial human trials in 2028 and bring 10 therapies to the clinic within the next decade.

Participated · Series D · Nov 2025

Synchron is a New York City–based neurotechnology company building the Stentrode platform, an endovascular brain-computer interface (BCI) that is delivered via catheter rather than open-brain surgery. Once implanted, the device interfaces with the motor cortex through the blood vessels and wirelessly transmits neural signals that can be translated into hands-free digital commands. Ten patients with paralysis have received the Stentrode across U.S. and Australian clinical trials, demonstrating early clinical adoption. Led by founder and CEO Tom Oxley, the company plans to use newly raised capital to scale operations and advance product development. Synchron’s ultimate goal is to commercialize a clinically viable, minimally invasive BCI for widespread medical use. Including the latest round, the company has secured $345 million in total funding to date, underlining strong investor confidence in its technology and market potential.